Aberdeen Group plc lessened its stake in ProQR Therapeutics N.V. (NASDAQ:PRQR – Free Report) by 98.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 119,394 shares of the biopharmaceutical company’s stock after selling 8,813,113 shares during the quarter. Aberdeen Group plc owned approximately 0.11% of ProQR Therapeutics worth $198,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Alpha Wealth Funds LLC acquired a new position in ProQR Therapeutics in the third quarter worth $41,000. RFG Advisory LLC raised its holdings in shares of ProQR Therapeutics by 236.8% during the second quarter. RFG Advisory LLC now owns 64,000 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 45,000 shares during the period. Bank of America Corp DE raised its holdings in shares of ProQR Therapeutics by 6.4% during the first quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock worth $300,000 after purchasing an additional 11,186 shares during the period. Axiom Investment Management LLC acquired a new stake in shares of ProQR Therapeutics during the first quarter worth $53,000. Finally, Walleye Capital LLC lifted its position in shares of ProQR Therapeutics by 2.7% in the 1st quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company’s stock worth $984,000 after buying an additional 15,744 shares during the last quarter. 32.65% of the stock is owned by institutional investors.
ProQR Therapeutics Stock Down 1.0%
PRQR stock opened at $1.04 on Friday. The company has a market capitalization of $109.58 million, a P/E ratio of -2.36 and a beta of 0.29. The company has a 50-day simple moving average of $1.49 and a 200 day simple moving average of $1.66. ProQR Therapeutics N.V. has a fifty-two week low of $1.00 and a fifty-two week high of $2.48.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on the stock. HC Wainwright dropped their price objective on shares of ProQR Therapeutics to $8.00 and set a “buy” rating on the stock in a research note on Thursday, October 1st. Weiss Ratings restated a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Thursday, November 12th. Chardan Capital reaffirmed a “buy” rating and set a $3.00 target price on shares of ProQR Therapeutics in a report on Thursday, October 1st. Wall Street Zen upgraded ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of ProQR Therapeutics in a report on Friday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $7.60.
View Our Latest Stock Report on ProQR Therapeutics
ProQR Therapeutics Company Profile
ProQR Therapeutics N.V. is a biotechnology company developing RNA-based medicines for genetic diseases. Its research centers on Axiomer, a platform designed to make targeted changes to RNA using the body’s naturally occurring editing machinery. Founded in 2012 and based in Leiden, the Netherlands, ProQR initially focused on RNA therapies for inherited retinal disorders, including Usher syndrome and Leber congenital amaurosis. The company later broadened its emphasis to RNA editing and continues to develop potential treatments for genetic conditions.
Featured Articles
- Five stocks we like better than ProQR Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding PRQR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ProQR Therapeutics N.V. (NASDAQ:PRQR – Free Report).
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
